礼来弃药涅槃重生,NektarIL-2通路激动剂在特应性皮炎中大获成功

药事纵横
26 Jun

6月24日,Nektar Therapeutics公司股价单日暴涨150%,其IL-2通路激动剂rezpegaldesleukin(简称rezpeg)在特应性皮炎(AD)的IIb期临床试验中取得了积极结果。这款曾被礼来(EliLilly)两年前放弃的药物,如今成功逆袭,也为Nektar与礼来的法律纠纷再添一把火。弃药重生:53%-61%EASI降幅碾压安慰剂Rezpeg是一种靶向IL-2受体复合物...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10